1. Home
  2. HRMY vs NBTB Comparison

HRMY vs NBTB Comparison

Compare HRMY & NBTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • NBTB
  • Stock Information
  • Founded
  • HRMY 2017
  • NBTB 1856
  • Country
  • HRMY United States
  • NBTB United States
  • Employees
  • HRMY N/A
  • NBTB N/A
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • NBTB Major Banks
  • Sector
  • HRMY Health Care
  • NBTB Finance
  • Exchange
  • HRMY Nasdaq
  • NBTB Nasdaq
  • Market Cap
  • HRMY 2.1B
  • NBTB 2.2B
  • IPO Year
  • HRMY 2020
  • NBTB N/A
  • Fundamental
  • Price
  • HRMY $35.99
  • NBTB $44.04
  • Analyst Decision
  • HRMY Strong Buy
  • NBTB Buy
  • Analyst Count
  • HRMY 9
  • NBTB 4
  • Target Price
  • HRMY $55.33
  • NBTB $51.50
  • AVG Volume (30 Days)
  • HRMY 531.4K
  • NBTB 167.3K
  • Earning Date
  • HRMY 10-28-2025
  • NBTB 10-27-2025
  • Dividend Yield
  • HRMY N/A
  • NBTB 3.32%
  • EPS Growth
  • HRMY 58.41
  • NBTB 7.37
  • EPS
  • HRMY 3.10
  • NBTB 2.77
  • Revenue
  • HRMY $772,527,000.00
  • NBTB $591,283,000.00
  • Revenue This Year
  • HRMY $20.09
  • NBTB $27.02
  • Revenue Next Year
  • HRMY $16.74
  • NBTB $11.44
  • P/E Ratio
  • HRMY $11.61
  • NBTB $16.07
  • Revenue Growth
  • HRMY 17.74
  • NBTB 14.42
  • 52 Week Low
  • HRMY $26.47
  • NBTB $37.31
  • 52 Week High
  • HRMY $41.61
  • NBTB $52.44
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 47.09
  • NBTB 55.44
  • Support Level
  • HRMY $36.50
  • NBTB $43.30
  • Resistance Level
  • HRMY $38.28
  • NBTB $45.28
  • Average True Range (ATR)
  • HRMY 0.95
  • NBTB 0.86
  • MACD
  • HRMY -0.17
  • NBTB 0.05
  • Stochastic Oscillator
  • HRMY 9.84
  • NBTB 63.42

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About NBTB NBT Bancorp Inc.

NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.

Share on Social Networks: